Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth P Goldstein

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Antimicrobial Agents and Chemotherapy|January 16, 2007
Bactericidal activity and resistance development profiling of dalbavancinBeth P Goldstein, Deborah C Draghi, Daniel J Sheehan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 30, 2003
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infectionsElyse Seltzer, Mary Beth Dorr, Beth P Goldstein, et al.
Diagnostic Microbiology and Infectious Disease|January 24, 2006
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)Ronald N Jones, Matthew G Stilwell, Helio S Sader, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2008
A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasisJosé A Vazquez, Jennifer A Schranz, Kay Clark, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemiaDavid S Krause, John Reinhardt, Jose A Vazquez, et al.
Journal of Clinical Microbiology|August 3, 2007
Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agentRobert P Rennie, Laura Koeth, Ronald N Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2004
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasisDavid S Krause, A E Simjee, Christo van Rensburg, et al.
The New England Journal of Medicine|June 15, 2007
Anidulafungin versus fluconazole for invasive candidiasisAnnette C Reboli, Coleman Rotstein, Peter G Pappas, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Antimicrobial Agents and Chemotherapy|January 16, 2007
Bactericidal activity and resistance development profiling of dalbavancinBeth P Goldstein, Deborah C Draghi, Daniel J Sheehan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 30, 2003
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infectionsElyse Seltzer, Mary Beth Dorr, Beth P Goldstein, et al.
Diagnostic Microbiology and Infectious Disease|January 24, 2006
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)Ronald N Jones, Matthew G Stilwell, Helio S Sader, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 12, 2008
A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasisJosé A Vazquez, Jennifer A Schranz, Kay Clark, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemiaDavid S Krause, John Reinhardt, Jose A Vazquez, et al.
Journal of Clinical Microbiology|August 3, 2007
Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agentRobert P Rennie, Laura Koeth, Ronald N Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2004
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasisDavid S Krause, A E Simjee, Christo van Rensburg, et al.
The New England Journal of Medicine|June 15, 2007
Anidulafungin versus fluconazole for invasive candidiasisAnnette C Reboli, Coleman Rotstein, Peter G Pappas, et al.
Pageof 2